Kobayashi Pharmaceuticals
Kobayashi Pharmaceuticals Co., Ltd., commonly known as Kobayashi, is a leading player in the pharmaceutical and consumer healthcare industry, headquartered in Japan. Established in 1907, the company has a rich history marked by innovation and growth, with significant operations across Asia and beyond. Kobayashi is renowned for its diverse range of products, including over-the-counter medications, personal care items, and health supplements. Their unique formulations and commitment to quality set them apart in a competitive market. With a strong focus on research and development, Kobayashi has achieved notable milestones, solidifying its position as a trusted name in healthcare. The company continues to excel, leveraging its expertise to meet the evolving needs of consumers, while maintaining a reputation for excellence in product efficacy and safety.
DitchCarbon Score
How does Kobayashi Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kobayashi Pharmaceuticals's score of 32 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kobayashi Pharmaceuticals's reported carbon emissions
In 2023, Kobayashi Pharmaceuticals reported significant carbon emissions, with total Scope 3 emissions amounting to approximately 177,000,000 kg CO2e. This figure highlights the company's substantial indirect emissions, which are critical in understanding its overall carbon footprint. For the previous years, the company disclosed Scope 2 emissions of about 1,566,000 kg CO2e in 2022 and 1,607,000 kg CO2e in 2021, indicating a slight decrease in emissions from purchased electricity over this period. In 2020, Kobayashi Pharmaceuticals reported combined Scope 1 and 2 emissions of approximately 23,536,000 kg CO2e, with Scope 1 emissions at about 5,679,000 kg CO2e and Scope 2 emissions at around 17,857,000 kg CO2e. Kobayashi Pharmaceuticals has set ambitious climate commitments through the Science Based Targets initiative (SBTi). The company aims to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 51% by 2030, using 2018 as the base year. Additionally, it has committed to a 15% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the necessary reductions to limit global warming to 1.5°C, demonstrating the company's proactive approach to climate action. Overall, Kobayashi Pharmaceuticals is actively working towards significant emissions reductions while addressing its broader environmental impact through its comprehensive climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 0,000,000 | - | - | - |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | - |
| Scope 3 | 66,000,000 | - | - | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kobayashi Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
